Paper: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Oral and Poster Abstracts617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster IIDiseases, AML, Clinically relevant, Myeloid Malignancies Hall B, Level 2 (Orange County Convention Center) Naveen Pemmaraju, MD1, Hagop M. Kantarjian, MD2, Joseph D. Khoury, MD3, Sanam Loghavi, MD3, Susan O’Brien, MD4,…

Read the full article here

Source: ash.confex.com

Categories: Hem/Oncs

Tags: BPDCN

Tweets with this article

Naveen Pemmaraju, MD

Yes. #BPDCN commonly occurs with or arises out of #CMML We have observed this for many years !! We Recently reported again (Pemmaraju et al ) at #ASH19 https://t.co/BTaT3zAld5 #hemepathjc this occurs so commonly that I propose a category called #PCHM https://t.co/GpL6M6PnPN

BPDCN: state of the art

Abstract. The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies

Naveen Pemmaraju, MD January 25, 2025

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Key PointsAdding navitoclax to ongoing ruxolitinib demonstrates durable responses and potential disease modification in relapsed/refractory MF.Thrombocytop

Naveen Pemmaraju, MD January 11, 2025

Article of the Week, Suggested by the BPDCN International Registry – OncoDaily

Article of the Week, Suggested by the BPDCN International Registry / Astghik Voskanyan, Blastic Plasmacytoid Dendritic Cell Neoplasm, BPDCN, BPDCN

Naveen Pemmaraju, MD January 10, 2025

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Key PointsAdding navitoclax to ongoing ruxolitinib demonstrates durable responses and potential disease modification in relapsed/refractory MF.Thrombocytop

Naveen Pemmaraju, MD January 9, 2025

Paper: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid…

Dr.Alberto Mussetti January 7, 2025

Homes for Healers

Meet Houston’s premier real estate agent for medical professionals. Whether you are moving within the city or relocating for the Texas Medical Center, I offer…

Naveen Pemmaraju, MD December 28, 2024

Paper: Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Bispecific Antibody…

Samer Al Hadidi, MD,MS,FACP December 28, 2024

Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review

The diagnosis of myeloid neoplasms with plasmacytoid dendritic cell (pDC) differentiation can be challenging due to immunophenotypic overlap requiring detailed characterization by flow cytometry an…

Naveen Pemmaraju, MD December 24, 2024

Welcome! You are invited to join a webinar: IACH Webinar- Post #ASH24: the Most Important MPN Studies. After registering, you will receive a confirmation email about joining the webinar.

Speaker: Naveen Pemmaraju Prof. Naveen Pemmaraju completed his Internal Medicine training at Johns Hopkins, in the Osler Medical Program, he subsequently completed both hematology and…

Naveen Pemmaraju, MD December 20, 2024

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms

In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic…

Naveen Pemmaraju, MD December 19, 2024

Related Articles